Healthcare Is Lagging but Biotech Offers Good Potential for Value and Trading…UPDATE-2 Sell Off Continues with SVB news
Update-2 3/9/23... Silicon Valley Bank Collapse triggers more selling in small cap biotechs.Sold XBI at $79 for 4% profit now at $75. Large cap biopharma holding up well in green. Jobs grew solidly but at a slower pace.So looking for a 25 bps rate increase. Risk off. Update-1 3/8/23...Sell-off...
SMID Life Science Stocks Update : The Momentum Run Is Over-Risk Off…Update-2 Bit of a Rally
Update-2 3/2 Better tape action today. Big winners: CRSP, CYRX, NTLA, NVTA, QDEL, PACB,SUPN. Review on Weekend. Cowen conference next week March 8 should help life science sector. Update-1 2/28 Risk Off when FED rules with rates rising. Equities fighting higher yields.Trading range S&P 500...
SMID Cap Life Science Update: Are You an Investor or Trader?
SMID Life Science Stocks: Investor or Trader? Despite choppy trading there is an upward tilt to life science stocks since 9/26/22 lows. Three stocks are strong holds: EVH,HOLX and QDEL. Can gene therapy break through in 2023? Our SMID (small and mid) life science portfolio had a good week...
Large Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers…Update-3 Healthcare gains, energy, techs lose…
2/17 Mid-day trading shows healthcare and biopharma gainers , tech losers as FEDspeak (Bullard, Nestor) reiterates rates rising juxtaposed with recession risk rising. Large cap winners: ABBV,AMGN, GILD, MRK etc. UNH up 1.38% XLV up holding above $130 November lows. 2/15 late day trading.........
When Small Cap Biotechs Lose Momentum: Are you an Investor or Trader? Update-2 QDEL
Update-2 2/17...QDEL beats on earnings and revenue of $3.37B. EPS of $13.80.Business combination with Ortho still in flux. Stock looks good on technical basis with accumulation. Good value with P/S 1.97, PE is 5.42 and P/FCF 6.45. Recommendation is a 2.0.---long QDEL added to position. Update-1...